U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07868328) titled 'A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies' on Oct. 05.
Brief Summary: This is a phase II study intended to evaluate the safety, tolerability and pharmacodynamics of NIO752 in participants with primary tauopathies. Eligible participants will be randomized to receive either NIO752 or placebo during the double-blind treatment period followed by an Open-label Extension (OLE).
Study Start Date: Oct. 23
Study Type: INTERVENTIONAL
Condition:
Progressive Supranuclear Palsy
Corticobasal Degeneration
Frontotemporal Lobar Degeneration
Tauopathies
Intervention:
DRUG: NIO752
Antisen...